Abstract: There is described herein a method of predicting disease progression risk in a subject with prostate cancer, the method comprising: a) providing a sample containing RNA and DNA material from tumour cells; b) determining or measuring values for substantially all of patient features listed for PRONTO-e or PRONTO-m in Table 6, and some or all reference or control features set forth in Table 6; c) comparing said patient features to the reference or control features; and d) computing a prediction score using a classifier that takes said patient feature values as input, the classifier having been previously trained on samples from a population of early prostate cancer patients.

Abstract: The present disclosure relates to a method of treating prostate cancer comprising administering to a subject in need thereof a therapeutically effective amount of a vasopressin analogue.

Abstract: The present disclosure relates to a method of treating prostate cancer comprising administering to a subject in need thereof a therapeutically effective amount of a vasopressin analogue.

Abstract: The present disclosure relates to a method of treating prostate cancer comprising administering to a subject in need thereof a therapeutically effective amount of a vasopressin analogue.

Abstract: The present disclosure relates to a method of treating prostate cancer comprising administering to a subject in need thereof a therapeutically effective amount of a vasopressin analogue.

Abstract: The present disclosure relates to a method of treating prostate cancer comprising administering to a subject in need thereof a therapeutically effective amount of a vasopressin analogue.

Abstract: The present disclosure relates to a method of treating prostate cancer comprising administering to a subject in need thereof a therapeutically effective amount of a vasopressin analogue.